Cost-Effectiveness Analysis of Adjuvant Alectinib versus Platinum-Based Chemotherapy in Resected ALK-Positive Non-Small-Cell Lung Cancer in the Chinese Health Care System.

ABSTRACT:

Objectives

The ALINE trial demonstrated the superiority of alectinib over platinum-based chemotherapy in resected Anaplastic Lymphoma Kinase (ALK)-positive non-small-cell lung cancer (NSCLC). Considering the high cost of alectinib, this study aimed to evaluate the economic value of alectinib compared to platinum-based chemotherapy for treating early-stage ALK-positive NSCLC from the perspective of the Chinese health care system.

Materials and methods

We developed a five-state Markov model with monthly cycles to estimate the lifetime costs, life-years (LYs), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) in terms of cost per LY gained and per QALY gained. Costs were obtained from database, expert opinions and published literature, and u

SUBMITTER: Wei Q 

PROVIDER: S-EPMC11571239 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature